No hol­i­day for biotech IPOs as Rally­bio and Sophia Ge­net­ics sub­mit their Nas­daq pitch­es

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

There’s no stop­ping the hot IPO mar­ket de­spite the long hol­i­day week­end, as an­oth­er two biotechs pre­pared their Nas­daq pitch­es late last Fri­day.

Mar­tin Mack­ay’s Rally­bio and the Swiss-based Sophia Ge­net­ics each pen­ciled in $100 mil­lion rais­es in their S-1 and F-1 fil­ings, re­spec­tive­ly, be­com­ing the lat­est biotechs to join the IPO craze that re­mains on pace to top last year’s records. Rally­bio and Sophia capped off a week that saw sev­er­al new fil­ings, in­clud­ing Jen­nifer Doud­na’s Cari­bou Bio­sciences, Paul Pe­ter Tak’s Can­del Ther­a­peu­tics, Ab­sci and Eras­ca.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.